Edesa Biotech, Inc. entered into an exclusive collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of its drug candidate, paridiprubart (EB05), in Japan. The agreement is for the treatment of acute respiratory distress syndrome (ARDS) and includes a significant upfront payment, potential milestone payments, and royalties.
Key Details
- Financial Terms: Edesa will receive a $12 million upfront payment, up to $55 million in development and regulatory milestones, and up to ¥12.0 billion in sales-based milestones. Edesa is also eligible for low double-digit tiered royalties on net sales in Japan.
- Agreement Scope: Kyorin gains exclusive rights to develop and commercialize paridiprubart for ARDS in Japan. Edesa retains all rights outside Japan and will manufacture and supply the drug to Kyorin.
- ATM Agreement Termination: Coinciding with this deal, Edesa announced the termination of its At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., effective November 16, 2026, with no termination penalties.